For years, Hilgenfeld and his team of researchers have been dedicated to the search of inhibitors of SARS-CoV. These substances block the activity of proteolytic enzymes in the virus, preventing thus the maturation. In the current state, the inhibitors developed by the research group of Hilgenfeld have proved effective in the therapy of mice infected by the coronavirus associated with SARS. Studies of the infettivologo German have also produced stable results in the experiments of the cultivation of human cells infected.
scientists have discovered that the 2019-nCov is similar to 80% to the SARS-CoV, and that the similarity between the proteases of these two viruses is equal to 96%. Hilgenfeld hoped that inhibitors developed by its team of researchers may help the research and development of new drugs which are useful in eradicating the new coronavirus. In an interview with China Media Group, Hilgenfeld has revealed that the experiments on the 2019-nCov will be conducted on mice and the study also includes a series of experiments in toxicological to eliminate the various side effects that could be generated by these substances. Finally, according to Hilgenfeld, the mass production of these medicines will be possible only through a series of clinical studies.
"The Republic will fight always in defense of the freedom of information, to its readers and to all those who have at heart the principles of democracy and civil coexistence"Carlo Verdelli SUBSCRIBERS TO REPUBLIC © Reproduction reserved Today on The lesson of the Emilia region. From the duel on the fear to the idea of community Stalingrad did not fall, The government will still suffer the Vote in Emilia-Romagna: from Bibbiano to the intercoms, the two months of gambling, Matteo Salvini Zingaretti: "Dialogue and responsibility. It is the line that wins”